Edwards Lifesciences (NYSE:EW) Upgraded by TD Cowen to Buy Rating

Edwards Lifesciences (NYSE:EW) was upgraded by research analysts at TD Cowen from a “hold” rating to a “buy” rating in a research report issued on Friday, Marketbeat.com reports. The firm presently has a $97.00 price objective on the medical research company’s stock. TD Cowen’s target price would suggest a potential upside of 14.73% from the stock’s previous close.

Several other analysts have also weighed in on EW. Evercore ISI reissued an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Monday. Robert W. Baird set a $87.00 price objective on shares of Edwards Lifesciences and gave the company a “neutral” rating in a research note on Tuesday, December 16th. Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a research report on Thursday, December 18th. Finally, Stifel Nicolaus increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

Edwards Lifesciences Stock Performance

Shares of EW opened at $84.55 on Friday. The stock has a market capitalization of $49.06 billion, a P/E ratio of 36.44, a P/E/G ratio of 3.45 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences has a 1 year low of $65.94 and a 1 year high of $87.89. The company’s fifty day moving average is $85.01 and its two-hundred day moving average is $80.25.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This represents a 24.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 56,805 shares of company stock valued at $4,775,995. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Econ Financial Services Corp acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $889,000. Randolph Co Inc bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $301,000. OMERS ADMINISTRATION Corp lifted its stake in shares of Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at $1,760,000. Finally, Arkadios Wealth Advisors bought a new stake in Edwards Lifesciences in the second quarter worth $300,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.